文献速递运动医学关节外科

按FDA审批路径分层的商用膝关节软骨修复技术文献证据评估

Evaluation of Commercially Available Knee Cartilage Restoration Techniques Stratified by FDA Approval Pathway.
PubMed 文献 · Am J Sports Med · 2021-09-15

该系统综述检索PubMed数据库,纳入470篇关于同种异体或自体软骨修复技术的文献,按FDA的351与361 HCT/P路径分层分析证据等级。结果显示351路径产品(全部为自体软骨细胞植入)更多为临床研究且含25项一级证据,361路径产品(94%为骨软骨同种异体移植)产品数量更多但证据等级较低。

要点

  • 351 HCT/P路径产品均为自体软骨细胞植入,临床研究占比80%,含25项一级证据。
  • 361 HCT/P路径产品94%为骨软骨同种异体移植,临床研究占比48%,无一级证据。
  • 两路径产品均有较强证据支持,但其余受监管产品证据极少或缺失。

核心结论

  • 351 HCT/P路径技术更可能有一级临床研究支持并发表于高影响力期刊。
  • 361 HCT/P路径监管的产品数量更多,但支持其使用的文献较少。
  • 自体软骨细胞植入与骨软骨同种异体移植均有较强证据支持,其余受监管产品证据极少或缺失。

研究设计与样本

  • 系统综述,证据等级4级,检索PubMed数据库并预设纳入与排除标准。
  • 纳入470篇关于同种异体或自体软骨修复技术的临床、临床前及实验室研究,排除 duplicates、系统综述及美国未上市产品。
  • 按FDA 351与361 HCT/P路径对文献分类,分析发表年份、类型、证据等级及发表数量。

主要发现

  • 351 HCT/P组全部为自体软骨细胞植入技术,361 HCT/P组94%为骨软骨同种异体移植。
  • 351 HCT/P组临床研究占比80%,显著高于361 HCT/P组的48%(P = .0001)。
  • 351 HCT/P组含25项一级研究,361 HCT/P组为0项(P < .0001)。
  • 351 HCT/P组发表于American Journal of Sports Medicine的文章数为71篇,361 HCT/P组为38篇(P = .18)。

关键数值与推荐

  • 351 HCT/P路径产品需更严格审批,其文献中一级研究25项,361 HCT/P路径为0项。
  • 361 HCT/P路径产品可用数量更多,但支持文献较少。

临床怎么用

  • 选择商用膝关节软骨修复技术时,可参考其FDA审批路径对应的文献证据等级。
  • 351 HCT/P路径产品(如自体软骨细胞植入)有较多一级临床证据支持。
  • 361 HCT/P路径产品(如骨软骨同种异体移植)产品丰富但高等级证据有限。

局限性

  • 本文为系统综述,证据等级4级,未报告具体偏倚风险评估方法。
  • 检索仅限PubMed数据库,可能遗漏其他数据库文献。
  • 排除系统综述及美国未上市产品,可能限制结论外推。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Commercially available products used in knee cartilage reconstructive and restorative surgical practices fall under unique US Food and Drug Administration (FDA) regulatory pathways that determine the level of evidence required to market each product. PURPOSE: To evaluate the levels of evidence in the literature supporting commercially available cartilage repair procedures stratified by FDA regulatory pathway (section 351 vs section 361 of "Human Cells, Tissues, and Cellular and Tissue-Based Products" [HCT/P] in the Code of Federal Regulation) with the hypothesis that products requiring approval under a stringent regulatory pathway (351 HCT/P) have higher levels of evidence in the literature supporting use and that products with a less stringent regulatory pathway (361 HCT/P) have a higher number of products available for use in the United States. STUDY DESIGN: Systematic review; Level of evidence, 4. METHODS: A search of the PubMed database was performed to identify all peer-reviewed articles pertaining to either allograft or autologous cartilage repair technologies. Predefined inclusion and exclusion criteria were used to find clinical, preclinical, and laboratory studies while excluding duplicates, systematic reviews, and products not available in the United States. Articles were categorized by regulatory pathway (351 and 361 HCT/P), and variables including publication year, type of publication, level of evidence, and number of publications were analyzed. RESULTS: After application of predefined criteria, 470 of 1924 articles were included in this study. The 351 HCT/P group was composed entirely of autologous chondrocyte implantation (ACI) technology; 94% of the 361 HCT/P group was composed of osteochondral allografts (OCA). The articles regarding 351 HCT/P were more likely to be clinical in nature than the articles on 361 HCT/P (80% vs 48%, respectively; P = .0001) and entailed significantly more level 1 studies (25 vs 0, respectively; P < .0001). Twice as many articles in the 351 HCT/P group were published in the American Journal of Sports Medicine compared with the 361 HCT/P group (71 vs 38, respectively; P = .18). CONCLUSION: Both ACI and OCA have robust evidence supporting their use, whereas the remaining regulated products have little or no supporting evidence. Technologies regulated by 351 HCT/P were more likely to be level 1 clinical studies and published in the highest impact journal. The 361 HCT/P pathway regulated many more products, with fewer articles supporting their use.

来源:Am J Sports Med,查看原文。版权归原作者所有。

引用

  1. Gudeman AS, Hinckel BB, Oladeji L, et al. Evaluation of Commercially Available Knee Cartilage Restoration Techniques Stratified by FDA Approval Pathway. Am J Sports Med. 2021. PMID: 34524032. doi:10.1177/03635465211037233

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。